Lipid nanoparticles for engineering next generation CAR T cell immunotherapy
Melgious Jin Yan Ang, Ann E. Metzloff, Ajay S. Thatte, Michael J. Mitchell
原始摘要（英文原文）· Original abstract
CAR T cell production. The review concludes with a discussion of safety, immunogenicity, scalability, manufacturing, and regulatory factors which will be essential as LNP-based CAR T cell immunotherapies move toward clinical translation.